Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (AVTX) from Perform to Outperform with a $35 price target.

April 16, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avalo Therapeutics was upgraded by Oppenheimer from Perform to Outperform with a new price target of $35.
Upgrades by analysts, especially from reputable firms like Oppenheimer, can lead to increased investor confidence and potential stock price increases. The significant raise in price target to $35 suggests a strong bullish outlook on AVTX by the analyst, which could influence market sentiment positively in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100